Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
16.60
-0.30 (-1.78%)
At close: Jun 27, 2025, 4:00 PM
18.21
+1.61 (9.70%)
After-hours: Jun 27, 2025, 5:17 PM EDT
Crescent Biopharma Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Crescent Biopharma stock ranges from a low of $22 to a high of $28. The average analyst price target of $25 forecasts a 50.60% increase in the stock price over the next year.
Price Target: $25.00 (+50.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +68.67% | Jun 25, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $22 | Buy | Initiates | $22 | +32.53% | Jun 18, 2025 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 15, 2021 |
| Raymond James | Raymond James | Buy Maintains $285 → $270 | Buy | Maintains | $285 → $270 | +1,526.51% | Aug 6, 2021 |
| Raymond James | Raymond James | Buy Maintains $270 → $285 | Buy | Maintains | $270 → $285 | +1,616.87% | Apr 29, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.